Lilly’s Ramucirumab Fails In Breast Cancer Trial, Clears Second Gastric Cancer Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly’s VEGF2-inhibitor failed to meet its primary endpoint of progression-free survival in a Phase III breast cancer study but met the primary endpoint of improved overall survival in an advanced gastric cancer trial.